Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026)

Neumora Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 5.73% year-over-year to $24.8 million in Q1 2026; TTM through Mar 2026 was $24.8 million, a 5.73% decrease from a year earlier, with the FY2025 full-year figure at $28.8 million, up 188.6% from the prior year.
• Accumulated Expenses slipped to $24.8 million in Q1 2026 per NMRA's latest filing, from $28.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $28.8 million in Q4 2025 and bottomed at $4.7 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $10.0 million (2023), against an average of $15.3 million.
• Across the five-year window, Accumulated Expenses sank 62.12% in 2024 and soared 463.78% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $8.4 million in 2022, then climbed by 19.18% to $10.0 million in 2023, then declined by 0.36% to $10.0 million in 2024, then soared by 188.6% to $28.8 million in 2025, then slipped by 13.97% to $24.8 million in 2026.
• Per Business Quant, the three latest NMRA Accumulated Expenses figures stand at $24.8 million (Q1 2026), $28.8 million (Q4 2025), and $25.0 million (Q3 2025).